Table 2

Univariate and multivariate analysis for PFS in 252 patients

PatientsNo
of patients n=252
No
of event n=57
Median
PFS
95% CIActuarial
5 years
PFS
(%)
Univariate analysisMultivariate analysis
HR (95% CI)P valueHR (95% CI)P value
Gender
 Female1302865.420.6 to 110.286.310.26210.090
 Male1222942.40.0 to 85.782.20.726 (0.415 to 1.270)0.568 (0.296 to 1.093)
Age, years
 ˂601563256.630.1 to 83.188.310.05210.662
 ≥60962528.83.4 to 54.277.71.811 (0.995 to 3.295)1.220 (0.501 to 2.973)
Presence of B symptoms
 No1833277.564.0 to 91.091.010.00010.021
 Yes692515.80.0 to 40.867.00.316 (0.171 to 0.582)0.406 (0.189 to 0.875)
Tumor sites
 Proximal or
≥2 components
398100.769.6 to 131.888.310.275
 Distal2134942.728.5 to 56.983.61.679 (0.663 to 4.253)
Lugano stage
 IE1502869.742.3 to 97.190.410.017
 IIE1022939.821.3 to 58.374.92.046 (1.135 to 3.689)
IPI risk group
 Low (intermediate) risk1243277.262.9 to 91.588.910.00010.314
 High risk or relapse1282515.83.7 to 27.980.63.908 (2.068 to 7.383)0.533 (0.157 to 1.812)
ECOG
 0–12144156.633.4 to 79.888.810.03710.047
 ≥2381639.80.0 to 83.658.22.020 (1.042 to 3.916)2.698 (1.015 to 7.174)
Histological analyses
 Non-GCB1733840.60.0 to 82.885.110.329
 GCB791949.723.1 to 76.382.81.356 (0.736 to 2.500)
Lactate dehydrogenase
 ˂200 U/L1823877.562.3 to 92.589.310.00010.000
 ≥200 U/L701912.34.8 to 19.872.622.384 (7.088 to 70.687)31.721 (8.271 to 121.650)
Helicobacter pylori with therapeutic response and TIL-Ts status
 Others1434537.819.1 to 56.570.510.00010.002
H. pylori-positive with pCR and high TIL-Ts10912120.293.2 to 147.288.18.110 (2.962 to 22.199)6.255 (1.930 to 20.268)
  • The p values with statistical significance are shown in bold.

  • Proximal: middle body, upper body, fundus or cardia; Distal: antrum, angle or lower body.

  • ECOG, Eastern Cooperative Oncology Group; GCB, germinal center B-cell; IPI, International Prognostic Index; pCR, complete pathological remission; PFS, progression-free survival; TIL-Ts, tumor-infiltrating T-lymphocytes.